T he Food and Drug Administration (FDA) has issued "Guideline for the St udy and Evaluation of Gender Differences in the Clinical Evaluation of Drugs" (1993) , which sets forth FDA's expectations about inclusion of both genders in drug development research. Furthermore, this guideline revises the section "Women of Childbearing Potential" in the 1977 guideline entitled "General Considerations for the Clinical Evaluation of Drugs" that excluded women of childbearing potential from participation in early studies of drugs.
Two major changes are addressed. First, FDA is withdrawing the restriction on the participation of women of childbearing potential in early clinical trials, including clinical pharmacology studies and early therapeutic studies. Second, FDA is formalizing expectations about inclusion of subjects of both genders in drug development; analyses of clinical data by gender; assessment of potential pharmacokinetic differences between genders; and, where appropriate, assessment of pharmacodynamic differences and ABOUT THE AUTHOR:
30 the conduct of specific additional studies in women.
Over the past decade, there has been growing concern that the drug development process does not produce adequate information about the effects of drugs in women. Analyses of published clinical trials in certain therapeutic areas, notably cardiovascular disease, have indicated little or no participation of women in many of the studies. For example, certain major studies of the role of aspirin in cardiovascular and cerebrovascular disease did not include women, and this omission left the scientific community with doubts about whether aspirin was, in fact, effective in women for these indications.
In addition, concern has been expressed that the 1977 policy excluding women of childbearing potential from early drug studies may have led to a more general lack of participation of women in drug development studies and thereby lack of information about drug effects. Also, the 1977 guideline, seen from the viewpoint of the 1990s, has appeared rigid and paternalistic, leaving virtually no room for the exercise of judgment by responsible female research subjects, physician investigators, and Institutional Review Boards (IRBs).
It is clear that pharmacokinetic and pharmacodynamic variations are important considerations to examine. For example, older people are more likely to have decreased renal function, which may cause drugs excreted by the kidney to accumulate; and women metabolize certain substances at rates different from men (for example, they metabolize alcohol more slowly).
A further reason for the lack of information about potential gender differences in drug response is the lack of specific studies of pharmacokinetics in women, even where gender related differences in pharmacokinetics might be expected or important. There are a variety of potential differences ofthis type, including differences due to menopause or the menstrual cycle, or to concomitant oral contraceptive or estrogen use, as well as differences based on different body fat proportion, and differences in weight or muscle mass. For example, small body size or muscle mass may lead to higher blood concentrations after a given dose of medication.
Pharmacodynamic differences in population subgroups, such as decreased sensitivity to beta blockers in the elderly, are fewer but have been reported.
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Much more attention to both pharmacokinetic and pharmacodynamic variations between genders is required.
The 1977 guideline policy stated that, in general, women of childbearing potential should be excluded from the earliest studies of a new drug; that is, phase 1 and early phase 2 studies. Phase 1 refers to the first introduction of a new drug into humans to study the basic tolerability ofthe drug, its metabolism, and its short term pharmacokinetics. Phase 2 refers to the initial controlled trials of a drug to study its effectiveness. The guideline stated that women of childbearing potential could be included in subsequent late phase 2 or phase 3 studies, assuming data detailing drug safety and effectiveness, animal teratogenicity, and female animal fertility studies had been completed.
As a result of the 1977 guideline, women generally have not been included in phase 1 nontherapeutic studies or in the earliest controlled effectiveness studies (i.e., early phase 2), except for studies of life threatening illnesses, such as acquired immune deficiency syndrome (AIDS) and cancer. The agency states that this exclusion has perhaps delayed appreciation of gender related variation in drug effects and may have perpetuated, in a subtle way, a view of the male as the primary focus of medicine and drug development, with women considered secondarily.
The FDA has reconsidered the 1977 guideline and has concluded that it should be revised. This does not reflect a lack of concern for potential fetal exposure or indifference to potential fetal damage, but rather the agency's opinion that exclusion of women from early trials is not medically necessary because the risk offetal exposure can be minimized by client behavior and laboratory testing. The agency believes that initial determinations about whether the risk is adequately addressed are properly left to clients, physicians, local IRBs, and sponsors, with appropriate review and guidance by FDA, as are all other aspects of the safety of proposed investigations.
The agency is, therefore, withdrawing the restriction on the participation of women of childbearing potential in early clinical trials, including clinical pharmacology studies (e.g., dose tolerance, bioavailability, and mechanism of action studies) and early therapeutic studies. It is expected that, in accordance with good medical practice, appropriate precautions against becoming pregnant and exposing a fetus to a potentially dangerous agent during the course of study will be taken by women participating in clinical trials.
It is also expected that women will receive adequate counseling about the importance of such precautions, that efforts will be made to be sure that a woman entering a trial is not pregnant at the time the trial begins (i.e., a pregnancy test detecting the beta subunit of the hCG molecule is negative), and that the woman participant is fully informed about the current state of the animal reproduction studies and any other information about the teratogenic potential ofthe drug.
The FDA advises that, in general, drugs should be studied prior to approval in clients representing the population likely to receive the drug once it is marketed. Study protocols also are expected to provide appropriate precautions against exposure of fetuses to potentially dangerous agents. When animal data suggest possible effects on fertility, such as decreased sperm production, special studies in humans may be needed to evaluate this potential toxicity. For most drugs, therefore, representa-
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COR N E R tives of both genders should be included in clinical trials in numbers adequate to allow detection of clinically significant gender related differences in drug response.
Pharmacokinetic issues related specifically to women that sh ou ld be considered during drug development are: 1) The influence of menstrual status on the drug's pharmacokinetics, inc! uding comparison s of premenopausal and po stmenopausal women and exa mina tion of within cycle changes; 2) the influence of concomitant supplementary estrogen treatment or sys t e m ic contraceptives (or a l contraceptive s, long acting progesteron e ) on the drug's pharmacokinetics; and 3) the influence of the drug on the pharmacokinetics of oral contraceptives.
The ag ency recognizes that this change in FDA's policy will not, by itself, cause drug companies or IRBs to alter restrictions they might impose on the participation of women of childbearing potential. However, as this guideline delineates , careful characterization of drug effects by gender is expected by the agency, and the FDA is determined to remove the unnecessa ry federal impediment to inelusion of women in the earliest stages of drug development. The agency is confident that the interplay of ethical, social, medical, legal, and political forces will allow greater participation of women in the early stages of clinical trials. • Reduc e c omplaints. lost -time ill nesse s and workers co m pe nsa t io n co sts I-<: st:ahli sh an l ':rgoHolnics Prograrn and l\·lal...c a [)iffcl-cncc in "i'our C O H "lp a n y 's Succc ss
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